Medications

Daclatasvir for hepatitis C: Added benefit not proven

The drug daclatasvir (trade name Daklinza) has been available since August 2014 for the treatment of adults with chronic hepatitis C (CHC) infection. The German Institute for Quality and Efficiency in Health Care (IQWiG) ...

Diseases, Conditions, Syndromes

New oral drug regimens cure hardest-to-treat hepatitis C

Two new pill-only antiviral drug regimens could provide shorter, more effective treatment options with fewer side effects for the majority of patients infected with hepatitis C, even those most difficult to treat, according ...

Diseases, Conditions, Syndromes

Experts call for stepped-up hepatitis battle

The world can beat the cancer-causing disease hepatitis if it raises its game, but treatment programmes need to go hand in hand with those tackling the likes of HIV, experts said Thursday.

Diseases, Conditions, Syndromes

Transmission of hepatitis C virus following antiviral treatment

Millions of people throughout the world are infected with hepatitis C virus (HCV). Left untreated, infection results in serious complications such as cirrhosis of the liver and cancer. Many HCV-infected patients respond well ...

Diseases, Conditions, Syndromes

Predicting the outcome of hepatitis C virus treatment

Millions of people throughout the world are infected with hepatitis C virus (HCV), which can lead to cirrhosis of the liver and cancer. Directly acting antiviral agents inhibit viral proteins and have been used to successfully ...

Oncology & Cancer

Patient factors affect accuracy of AFP detection of liver cancer

(HealthDay)—Measurement of α-fetoprotein (AFP) detects hepatocellular carcinoma (HCC) most accurately in patients without hepatitis C virus (HCV) infection, according to a study published in the May issue of Clinical Gastroenterology ...

page 6 from 11